The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Improvements in HRQoL after exa-cel in patients with transfusion-dependent β-thalassemia
In this video, Haydar Frangoul, MD, The Children’s Hospital at TriStar Centennial, Nashville, TN, summarizes health-related quality of life (HRQoL) data emerging from the CLIMB THAL-111 trial (NCT03655678), which is evaluating exagamglogene autotemcel (exa-cel) in patients with β-thalassemia. These data show that HRQoL improved across all endpoints for patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Jazz Pharmaceuticals: Speakers Bureau; Editas Medicine: Consultancy; Vertex Pharmaceuticals: Consultancy, Board of Directors/Advisory Committee; Rocket Pharmaceuticals: Consultancy, Member of DSMB for a study.
